ArticleFrontiers in cardiovascular medicine2025
Biogenic polymer based patches for congenital cardiac surgery: future development of implants.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biogenic polymer-based heart valve for congenital cardiac surgery.JTCVS open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Despite advancements in surgical techniques, many patients born with congenital heart defects (CHD) require repeated reinterventions due to the limitations of materials used in congenital cardiac surgery (CCS). Traditional biogenic polymers, such as bovine or equine pericardium, are prone to calcification, have limited durability, and fail to adapt to the growth of infants. This study aims to address these challenges by investigating bacterial cellulose (BC) as a promising material for CCS. Methods: Variability in patch quality from previous studies was addressed by refining the production protocol taking advantage of optical density (OD) measurements. After a 72 h incubation, patches were harvested and tested mechanically with burst pressure and uniaxial strain testing. BC's biomechanical properties were further explored by modifying nutrient concentrations, creating different media groups (N10, N30, N50). Hybrid patches combining BC with electrospun polyurethane (ESP-PU) were developed using a specially designed 3D-printed flask to ensure uniform coating and integration. Results: The initial bacterial concentration significantly influenced cellulose yield and growth rate, with static cultures outperforming shaken ones. Nutrient-enriched media (N10, N30, N50) produced cellulose with greater elasticity and strength compared to standard C-Medium, with stiffness correlating to nutrient concentration. Inflation tests showed that N10 and N30 samples withstood higher pressures than N50, which, despite being stiffer, performed worse under rapid inflation. All samples, however, maintained pressures above physiological levels. Scanning electron microscopy analysis confirmed effective BC coating of PU fibres without altering BC fibre orientation or bacterial activity. Conclusion: BC patches demonstrated burst pressure resistance above 1,400 mmHg. BC's elasticity can be tailored, and in combination with ESP-PU, an innovative hybrid material can be produced, positioning BC as a promising biomaterial for future CCS implant development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.